HC Wainwright Cuts Invivyd (NASDAQ:IVVD) Price Target to $10.00

Invivyd (NASDAQ:IVVD) had its price target decreased by HC Wainwright from $15.00 to $10.00 in a research report sent to investors on Wednesday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Invivyd’s Q4 2024 earnings at ($0.35) EPS, FY2024 earnings at ($1.63) EPS, Q1 2025 earnings at ($0.02) EPS, Q2 2025 earnings at $0.02 EPS, Q3 2025 earnings at $0.05 EPS, Q4 2025 earnings at $0.08 EPS, FY2025 earnings at $0.15 EPS, FY2026 earnings at ($0.15) EPS, FY2027 earnings at $0.04 EPS and FY2028 earnings at $0.29 EPS.

Separately, EF Hutton Acquisition Co. I raised Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th.

Invivyd Stock Performance

Shares of IVVD stock opened at $0.70 on Wednesday. Invivyd has a 12-month low of $0.69 and a 12-month high of $5.20. The business’s fifty day simple moving average is $0.97 and its 200-day simple moving average is $1.23. The company has a market cap of $83.90 million, a PE ratio of -0.36 and a beta of 0.65.

Hedge Funds Weigh In On Invivyd

Several hedge funds have recently made changes to their positions in the company. Proficio Capital Partners LLC purchased a new stake in Invivyd during the 3rd quarter valued at about $27,000. XTX Topco Ltd boosted its position in Invivyd by 68.1% in the second quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock valued at $42,000 after buying an additional 15,376 shares during the last quarter. SG Americas Securities LLC increased its holdings in Invivyd by 198.6% in the 2nd quarter. SG Americas Securities LLC now owns 37,893 shares of the company’s stock worth $42,000 after buying an additional 25,201 shares during the period. Cornercap Investment Counsel Inc. purchased a new position in Invivyd during the 2nd quarter worth approximately $86,000. Finally, Rhumbline Advisers raised its position in Invivyd by 4,434.1% during the 2nd quarter. Rhumbline Advisers now owns 84,017 shares of the company’s stock worth $92,000 after buying an additional 82,164 shares during the last quarter. 70.36% of the stock is owned by institutional investors and hedge funds.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.